natgillin/translations-raw huggingface dataset:
The onset of immunity has been demonstrated from: - 3 weeks after the primary vaccination for the panleucopenia and leukaemia components - 4 weeks after the primary vaccination for the calicivirus and rhinotracheitis virus components.
Nastop imunosti je bil dokazan od: - 3 tedne po prvem cepljenju za komponenti panlevkopenija in levkemija - 4 tedne po prvem cepljenju za komponenti kalicivirus in virusni rinotraheitis.
SUSPENSION VIAL
VIALE SUSPENZIJE
Re-vaccinations:
Revakcinacija:
For the leukaemia component, protection against persistent viraemia is observed in 73% of cats 3 weeks after their first vaccine injection.
Za komponento levkemije se je zaščita pred trajno viremijo pojavila pri 73 odstotkih mačk tri tedne po prejemu prve injekcije cepiva.
Lyophilisate and suspension for suspension for injection.
Liofilizat in suspenzija za suspenzijo za injiciranje.
The vaccine can be used as a booster for kittens or cats previously vaccinated with FELIGEN RCP and LEUCOGEN separately.
Cepivo se lahko uporabi kot poživilni odmerek za mačje mladiče in mačke, ki so bile predhodno cepljene posebej z zdraviloma FELIGEN CRP in LEUCOGEN.
Excipient: Stabilizing buffer containing gelatin: to
Pufer za stabilizacijo, ki vsebuje želatino: do
The antigenic suspension is adjuvanted with an aluminium hydroxide gel and with a purified extract of Quillaja saponaria.
Antigenski suspenziji je dodan gel aluminijevega hidroksida ter prečiščen izvleček Quillaja saponaria.
Therefore, a test for presence of FeLV before vaccination is recommended.
Zato pred cepljenjem priporočamo test za prisotnost virusa FeLV.
No adverse reactions were observed after an overdose administration (10 doses of lyophilisate and 2 doses of suspension) of the veterinary medicinal product other than those mentioned in section 4.6 except local reactions that can last longer (from 5 to 6 weeks at the most).
Po dajanju prevelikega odmerka (10 odmerkov liofilizata in 2 odmerka suspenzije) zdravila za uporabo v veterinarski medicini ni bilo opaziti neželenih učinkov, razen tistih, ki so omenjeni v poglavju 4.6, z izjemo lokalnih reakcij, ki lahko trajajo dlje časa (od 5 do 6 tednov največ).
Lyophilisate: White pellet.
Liofilizat: bela peleta.
Purified extract of Quillaja saponaria
Prečiščen izvleček Quillaja saponaria
1.3 ml before freeze-drying
1,3 ml pred liofilizacijo
4.7 Use during pregnancy, lactation or lay
Uporaba v obdobju brejosti, laktacije ali nesnosti
A moderate and transient local reaction (<2 cm) is commonly observed after the first injection.
Po prvem injiciranju je pogosto opažena zmerna in prehodna lokalna reakcija (<2 cm).
METHOD AND ROUTE(S) OF ADMINISTRATION
NAČIN IN POT(I) UPORABE
After the primary vaccination course, the duration of immunity lasts for one year for all components.
Po prvem krogu cepljenja je trajanje imunosti eno leto za vse komponente.
Excipient: Stabilizing buffer containing gelatin to 1.3 ml before freeze-drying
Pufer za stabilizacijo, ki vsebuje želatino do 1,3 ml pred liofilizacijo
1 dose
1 odmerek
Maternally derived antibodies, especially those against feline panleucopenia virus, can negatively influence the immune response to vaccination.
Maternalna protitelesa, še posebej tista proti virusu mačje panleukopenije, lahko negativno vplivajo na imunski odziv na cepivo.
Box of 10 or 50 lyophilisate vials and 10 or 50 suspension vials
Škatla z 10 ali 50 vialami liofilizata in 10 ali 50 vialami suspenzije.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Pogostnost neželenih učinkov je določena po naslednjem dogovoru: - zelo pogosti (neželeni učinki se pokažejo pri več kot 1 od 10 zdravljenih živali), - pogosti (pri več kot 1, toda manj kot 10 živali od 100 zdravljenih živali), - občasni (pri več kot 1, toda manj kot 10 živali od 1.000 zdravljenih živali), - redki (pri več kot 1, toda manj kot 10 živali od 10.000 zdravljenih živali), -zelo redki (pri manj kot 1 živali od 10.000 zdravljenih živali, vključno s posameznimi primeri).
Shelf life after reconstitution: use immediately.
Rok uporabnosti po rekonstituciji: uporabite takoj.
Per dose of 1 ml:
Na odmerek 1 ml:
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated)
Pogostnost neželenih učinkov je določena po naslednjem dogovoru: - zelo pogosti (neželeni učinki se pokažejo pri več kot 1 od 10 zdravljenih živali), - pogosti (pri več kot 1, toda manj kot 10 živali od 100 zdravljenih živali), - občasni (pri več kot 1, toda manj kot 10 živali od 1.000 zdravljenih živali), - redki (pri več kot 1, toda manj kot 10 živali od 10.000 zdravljenih živali),
Reconstitute one dose of lyophilisate with one dose of suspension, shake gently and administer immediately.
En odmerek liofilizata rekonstituirajte z enim odmerkom suspenzije, rahlo pretresite in takoj aplicirajte.
Plastic or cardboard box of 50 lyophilisate vials and 50 suspension vials.
Plastična ali kartonska škatla s 50 vialami liofilizata in 50 vialami suspenzije.
Plastic or cardboard box of 10 lyophilisate vials and 10 suspension vials.
Plastična ali kartonska škatla z 10 vialami liofilizata in 10 vialami suspenzije.
Administer subcutaneously one dose (1ml) of the veterinary medicinal product according to the following regimen of vaccination.
En odmerek zdravila (1ml) za uporabo v veterinarski medicini dajte subkutano po naslednjem programu cepljenja.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
DATUM ZADNJE ODOBRITVE NAVODIL ZA UPORABO
Live attenuated feline panleucopenia virus (strain LR 72)
Živ oslabljeni virus mačje panlevkopenije (sev LR 72)
Reconstitute one dose of lyophilisate with one dose (1ml) of suspension, shake gently and administer immediately.
En odmerek liofilizata rekonstituirajte z enim odmerkom (1ml) suspenzije, rahlo pretresite in takoj aplicirajte.
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
A. PROIZVAJALEC BIOLOŠKE UČINKOVINE IN PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ
THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”
BESEDILO “ZDRAVILO SHRANJUJTE NEDOSEGLJIVO OTROKOM ”
The feline calicivirus and feline panleucopenia virus vaccine strains can spread.
Vakcinalni sevi kalicivirusa mačk in virusa mačje panlevkopenije se lahko širijo.
- feline viral rhinotracheitis to reduce clinical signs and viral excretion, - feline panleucopenia to prevent leucopenia and to reduce clinical signs, - feline leukaemia to prevent persistent viraemia and clinical signs of the related disease.
- virusnemu rinotraheitisu mačk za zmanjšanje kliničnih znakov in izločanja virusa, - panlevkopeniji mačk za preprečevanje levkopenije in zmanjšanje kliničnih znakov, - levkemiji mačk, za preprečevanje trajne viremije in kliničnih znakov povezane bolezni.
Minimum quantity of purified p45 FeLV-envelope antigen
Minimalna količina prečiščenega antigena ovojnice p45 FeLV 102 µg
4.4 Special warnings for each target species
Posebna opozorila za vsako ciljno vrsto :
Active substance:
Pomožna snov:
Following a first booster vaccination one year after the primary vaccination course, a duration of immunity of 3 years has been demonstrated for the leukaemia component.
Po prvem poživilnem cepljenju leto po prvem krogu cepljenja je bilo za komponento levkemije dokazano trajanje tri leta.
Not all pack sizes may be marketed
Ni nujno, da so v prometu vsa navedena pakiranja
Name and address of the manufacturer responsible for batch release
Ime in naslov proizvajalca zdravila, odgovornega za sproščanje serij
Live attenuated feline viral rhinotracheitis virus (strain F2)
Živ oslabljeni virus mačjega virusnega rinotraheitisa (sev F2)
EU/2/09/097/001-002
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/09/097/001-002
Sodium chloride Disodium phosphate anhydrous Potassium dihydrogen phosphate Aluminium hydroxide gel Quillaja saponaria Water for injections
Natrijev hidrogenfosfat, brezvodni Kalijev dihidrogenfosfat Aluminijev hidroksid (gel) Quillaja saponaria Voda za injekcije
Visual aspect:
Videz:
Vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia.
Cepivo proti virusnemu rinotraheitisu mačk, kalicivirozi mačk, panlevkopeniji mačk in mačji levkemiji.
LYOPHILISATE VIAL
VIALA LIOFILIZATA
Suspension for LEUCOFELIGEN FeLV/RCP, for cats
Suspenzija za LEUCOFELIGEN FeLV/RCP za mačke
Only feline leukaemia virus (FeLV) negative cats should be vaccinated.
Cepijo se lahko samo mačke, ki nimajo virusa mačje levkemije (so FeLV negativne).
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo V primeru nenamernega samo-injiciranja se takoj posvetujte z zdravnikom in mu pokažite navodilo za uporabo ali ovojnino.
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.
Zdravila ne smete uporabljajte po datumu izteka roka uporabnosti navedenega na nalepki po EXP. Rok uporabnosti po rekonstrukciji v skladu z navodili: uporabite takoj.
LEUCOFELIGEN FeLV/RCP, lyophilisate for cats
LEUCOFELIGEN FeLV/RCP liofilizat za mačke
Live attenuated feline calicivirus (strain F9)
Živ oslabljeni mačji kalicivirus (sev F9)
- feline calicivirosis to reduce clinical signs, - feline viral rhinotracheitis to reduce clinical signs and viral excretion, - feline panleucopenia to prevent leucopenia and to reduce clinical signs,
- kalicivirozi mačk za zmanjšanje kliničnih znakov - virusnemu rinotraheitisu mačk za zmanjšanje kliničnih znakov in izločanja virusa - panlevkopeniji mačk za preprečevanje levkopenije in zmanjšanje kliničnih znakov - levkemiji mačk za preprečevanje trajne viremije in kliničnih znakov povezane bolezni.
Read the package leaflet before use Subcutaneous use
Pred uporabo preberite navodilo.
Following a first booster vaccination one year after the primary vaccination course, subsequent vaccinations can be performed at intervals of three years for the leukaemia component.
Za komponento levkemije se lahko po prvem poživilnem cepljenju leto po prvem krogu cepljenja izvede nadaljnja cepljenja v intervalih po tri leta.
LEUCOFELIGEN FeLV/RCP lyophilisate and suspension for suspension for injection for cats
LEUCOFELIGEN FeLV/RCP liofilizat in suspenzija za suspenzijo za injiciranje za mačke
Type I glass vial containing one dose (1 ml) of the adjuvanted liquid, with a 13 mm-diameter butyl elastomer stopper and set with an aluminium capsule.
Viala iz stekla tipa I, ki vsebuje en odmerek (1ml) tekočine z dodatki, z zamaškom iz butil elastomera, premera 13 mm, ter komplet z aluminijasto kapsulo.
A type I glass vial containing one dose (1 ml) of the adjuvanted liquid vaccine, with a 13 mm-diameter butyl elastomer stopper and set with an aluminium capsule.
Viala iz stekla tipa I, ki vsebuje en odmerek (1ml) tekočine cepiva z dodatki, z zamaškom iz butil elastomera, premera 13 mm in zaprta z aluminijasto zaporko.
Potassium hydroxide Lactose monohydrate Glutamic acid
Kalijev hidroksid Laktoza monohidrat Glutaminska kislina Kalijev dihidrogenfosfat Kalijev hidrogenfosfat Voda za injekcije Natrijev klorid
A type I glass vial containing one dose of freeze-dried attenuated live viral components with a butyl elastomer stopper.
Viala iz stekla tipa I, ki vsebuje en odmerek liofiliziranih oslabljenih živih virusnih komponent, z zamaškom iz butil elastomera.
Marketing authorisation holder and manufacturer responsible for the batch release:
Imetnik dovoljenja za promet z zdravilom in proizvajalec odgovoren za sproščanje serij: VIRBAC
Administer subcutaneously one dose (1 ml) of the veterinary medicinal product according to the following regimen of vaccination.
En odmerek zdravila za uporabo v veterinarski medicini dajte subkutano po naslednjem programu cepljenja.
PACKAGE LEAFLET: LEUCOFELIGEN FeLV/RCP lyophilisate and suspension for suspension for injection for cats
NAVODILO ZA UPORABO LEUCOFELIGEN FeLV/RCP liofilizat in suspenzija za suspenzijo za injiciranje za mačke
Excipient: Buffered isotonic solution to
Pomožna snov: Puferirana izotonična raztopina do
Lot {number}
Serija {številka}
ère avenue 2065 m LID 06516 Carros France
ère avenue 2065 m LID 06516 Carros Francija
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje veterinarsko zdravilo: V primeru nenamernega samo-injiciranja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali ovojnino.
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
Disodium phosphate anhydrous
Natrijev hidrogenfosfat, brezvodni
This check should be repeated at intervals.
To preverjanje je treba ponavljati v presledkih.
Two-year clinical studies have shown maintenance of this effect.
Dvoletne klinične študije so pokazale vzdrževanje tega učinka.
if you drink alcohol excessively (either every day or only from time to time).
- če prekomerno uživate alkohol (bodisi dnevno ali občasno).
Absolute bioavailability is greater than 80%.
Absolutna biološka uporabnost je večja od 80%.
if you have blood in your urine that your doctor has not checked.
- če imate kri v urinu, ki ga zdravnik ni preiskal.
The level of sugar in your blood or urine should be checked regularly.
Raven sladkorja v krvi ali urinu je treba redno preverjati.
The recommended dose is one tablet taken twice daily.
Priporočeni odmerek je ena tableta dvakrat na dan.
Date of first authorisation: 11 December 2007 Date of latest renewal: 10 November 2017
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 11 december 2007 Datum zadnjega podaljšanja: 10 November 2017
The data presented during the current reporting period did not provide new information that would allow for further reduction, mitigation, or characterisation of these risks.
Podatki, predloženi v tekočem obdobju poročanja, niso zagotovili novih informacij, ki bi omogočale dodatno zmanjšanje, omilitev ali opredelitev teh tveganj.
Your doctor will take this into account when treating your diabetes.
Zdravnik bo to upošteval pri zdravljenju vaše sladkorne bolezni.
The potential risk for humans is unknown.
Možno tveganje za človeka ni znano.
If this applies to you, use appropriate contraception to avoid the possibility of an unplanned pregnancy.
Če se to nanaša na vas, vzemite primerno kontracepcijo, da preprečite možnost nenačrtovane nosečnosti.
However, this did not lead to an increase in mortality in this study.
Vendar to ni vodilo k povečanju smrtnosti v tej študiji.
if you have or have ever had bladder cancer.
- če imate ali ste kdaj imeli raka sečnega mehurja.
You should not use this medicine if you are pregnant.
Ne jemljite tega zdravila, če ste noseči.
Metformin may act via three mechanisms:
Metformin lahko deluje na tri načine:
The study population had an average age of 62 years; the average duration of diabetes was 9.5 years.
Starost študijske populacije je bila v povprečju 62 let; povprečno trajanje sladkorne bolezni je bilo 9,5 let.
Approximately half of the study population had at least two of the cardiovascular history entry criteria.
Približno polovica študijske populacije je ustrezala vsaj dvema vstopnima kriterijema kardiovaskularne anamneze.
Although in very rare cases fatal outcome has been reported, causal relationship has not been established.
Čeprav so v zelo redkih primerih poročali o smrtnem izidu, vzročna povezava ni bila ugotovljena.
A risk to the newborns/infants cannot be excluded.
Tveganja za dojenega novorojenčka/dojenčka ne moremo izključiti.
Pregnancy and breast-feeding - you must tell your doctor if you are pregnant, think you may be pregnant or are planning to have a baby.
Nosečnost in dojenje - Svojemu zdravniku morate povedati, če ste noseči, menite, da bi lahko bili noseči ali načrtujete zanositev.
The estimated volume of distribution in humans is 0.25 L/kg.
Porazdelitev Ocenjeni volumen porazdelitve pri človeku je 0,25 l/kg.
not known not known
neznana neznana
if you have a severe infection or are dehydrated.
- če imate hujšo okužbo ali ste dehidrirani.
Some epidemiological studies have suggested a similarly increased risk of fracture in both men and women.
Nekatere epidemiološke študije so pokazale podobno povečano tveganje za zlome tako pri moških kot ženskah.
Steady state is achieved after 4-7 days of dosing.
Stanje dinamičnega ravnovesja je doseženo po 4-7 dnevih odmerjanja.
As a consequence, the conditions or restrictions with regards to the safe and effective use of the medicinal product should be updated to remove the additional risk minimisation measures.
Zaradi tega je treba pogoje ali omejitve v zvezi z varno in učinkovito uporabo zdravila posodobiti tako, da se odpravijo dodatni ukrepi za zmanjševanje tveganj.
However patients who experience visual disturbance should be cautious when driving or using machines.
Vendar pa morajo biti bolniki, ki so imeli motnje vida, previdni pri vožnji ali upravljanju strojev.
Three of the six identified metabolites are active (M-II, M-III, and M-IV).
Trije od šestih znanih presnovkov so aktivni (M-II, M-III in M-IV).
The presence of microcrystals exacerbated the hyperplastic response but was not considered to be the primary cause of hyperplastic changes.
Prisotnost mikrokristalov je poslabšala hiperplastični odgovor, vendar se ne šteje za glavni vzrok nastalih hiperplastičnih sprememb.
The relevance of this finding is unknown.
Pomen te ugotovitve ni znan.
if you retain water (fluid retention) or have heart failure problems in particular if you are over 75 years old.
- če zadržujete vodo (zastajanje tekočine v telesu) ali imate težave s srčnim popuščanjem, zlasti če ste starejši od 75 let.
In particular, patients have experienced the following serious side effects:
Pri bolnikih so se pojavili zlasti naslednji resni neželeni učinki:
Tablets should be swallowed with a glass of water.
Tablete je treba pogoltniti s kozarcem vode.
On this basis M-IV contribution to efficacy is approximately three-fold that of pioglitazone, whilst the relative efficacy of M-II is minimal.
Na tej podlagi je delež učinkovitosti M-IV enak približno trikratniku deleža pioglitazona, medtem ko je relativna učinkovitost M-II minimalna.
Approximately one third of patients were receiving insulin in combination with metformin and/or a sulphonylurea.
Približno ena tretjina bolnikov je prejemala insulin v kombinaciji z metforminom in/ali sulfonilsečnino.
Women of childbearing potential / Contraception in males and females
Ženske v rodni dobi / Kontracepcija pri moških in ženskah
The maximum reported dose of 120 mg/day for four days, then 180 mg/day for seven days was not associated with any symptoms.
Najvišji poročani odmerek 120 mg/dan štiri dni, zatem pa 180 mg/dan sedem dni, ni bil povezan s kakršnimikoli simptomi.
Your blood sugar could fall below the normal level and can be increased by taking sugar.
Krvni sladkor lahko pade pod normalno raven in se lahko poveča z zaužitjem sladkorja.
Children and adolescents Use in children and adolescents under 18 years is not recommended.
Otroci in mladostniki Uporaba tega zdravila pri otrocih in mladostnikih, mlajših od 18 let, ni priporočljiva.
Takeda Ireland Limited, Bray Business Park, Kilruddery, County Wicklow, Ireland Delpharm Novara S.r.l., Via Crosa, 86, I-28065 Cerano (NO), Italy Lilly S.A., Avda.
Takeda Ireland Limited, Bray Business Park, Kilruddery, County Wicklow, Irska Delpharm Novara S.r.l., Via Crosa, 86, I-28065 Cerano (NO), Italija Lilly S.A., Avda.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu
4 Gastrointestinal disorders occur most frequently during initiation of therapy and resolve spontaneously in most cases.
4 Gastrointestinalne motnje se najpogosteje pojavijo ob začetku zdravljenja in v večini primerov spontano prenehajo.
Immune System Disorders hypersensitivity and allergic reactions1
Bolezni imunskega sistema preobčutljivost in alergijske reakcije1
The relevance to humans of the tumourigenic findings in the male rat cannot be excluded.
Pomena za ljudi glede tumorogenih ugotovitev pri samcih podgan ni mogoče izključiti.
At least once a year (more often if you are elderly or have kidney problems) your doctor will check that your kidneys are working normally.
Vsaj enkrat letno (pogosteje, če ste starejši ali imate težave z ledvicami) bo zdravnik preveril, če ledvice pravilno delujejo.
Absorption is not influenced by food intake.
Vnos hrane ne vpliva na absorpcijo.
In patients who fail to show an adequate response, pioglitazone should be discontinued.
Pri bolnikih, ki ne pokažejo ustreznega odziva, je treba pioglitazon ukiniti.
It is recommended that you carry some sugar lumps, sweets, biscuits or sugary fruit juice.
Priporočljivo je, da imate pri sebi nekaj kock sladkorja, bombone, piškote ali sladek sadni sok.
If you wish to become pregnant, your doctor will advise you to discontinue this medicine.
Če želite zanositi, vam bo zdravnik svetoval, da prenehate z jemanjem tega zdravila.
In animals, only a small amount of unchanged pioglitazone can be detected in either urine or faeces.
Pri živalih se lahko zazna samo majhno količino nespremenjenega pioglitazona v urinu ali blatu.
Many of these patients reported concurrent peripheral oedema.
Pri mnogih od teh bolnikov so poročali o sočasnem perifernem edemu.
de la Industria 30, 28108 Alcobendas, Madrid, Spain
de la Industria 30, 28108 Alcobendas, Madrid, Španija
Packs of 14, 28, 30, 50, 56, 60, 90, 98 and 180 tablets.
Pakiranja po 14, 28, 30, 50, 56, 60, 90, 98 in 180 tablet.
Patients and/or care-givers should be informed on the risk of lactic acidosis.
Bolnike in/ali negovalce je treba opozoriti na tveganje laktacidoze.
Pioglitazone and all active metabolites are extensively bound to plasma protein (> 99%).
Pioglitazon in vsi aktivni presnovki se v veliki meri vežejo na plazemske beljakovine (> 99%).
After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c).
Po začetku zdravljenja s pioglitazonom je treba bolnike pregledati po 3 do 6 mesecih, da se oceni ustreznost odziva na zdravljenje (npr. zmanjšanje HbA1c).
Almost half of the patients had a previous myocardial infarction and approximately 20% had had a stroke.
Skoraj polovica bolnikov je predhodno doživela miokardni infarkt in približno 20% je doživelo kap.
The reports of oedema were generally mild to moderate and usually did not require discontinuation of treatment.
Edemi, o katerih so poročali, so bili v splošnem blagi do zmerni in običajno niso zahtevali prekinitve zdravljenja.
Do not take Glubrava: if you are allergic to pioglitazone, metformin or any of the other ingredients of this medicine (listed in section 6).
Ne jemljite zdravila Glubrava: - če ste alergični na pioglitazon, metformin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Do not use this medicine after the expiry date which is stated on the carton and the blister after “EXP”.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake “EXP”.
Linearity/non-linearity
Linearnost/Nelinearnost
In addition, increased fatty deposition and infiltration were observed.
Poleg tega so opažali povečano odlaganje in infiltracijo maščob.